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Background-—Timely reperfusion after ST-elevation myocardial infarction (STEMI) improves survival. Guidelines recommend
primary percutaneous coronary intervention (PPCI) within 90 minutes of arrival at a PCI-capable hospital. The alternative is
ﬁbrinolysis within 30 minutes for those in those for whom timely transfer to a PCI-capable hospital is not feasible.
Methods and Results-—We identiﬁed STEMI patients receiving reperfusion therapy at 229 hospitals participating in the Get With
the Guidelines—Coronary Artery Disease (GWTG-CAD) database (January 1, 2003 through December 31, 2008). Temporal trends in
the use of ﬁbrinolysis and PPCI, its timeliness, and in-hospital mortality outcomes were assessed. We also assessed predictors of
ﬁbrinolysis versus PPCI and compliance with performance measures. Defect-free care was deﬁned as 100% compliance with all
performance measures. We identiﬁed 29 190 STEMI patients, of whom 2441 (8.4%) received ﬁbrinolysis; 38.2% of these patients
achieved door-to-needle times ≤30 minutes. Median door-to-needle times increased from 36 to 60 minutes (P=0.005) over the
study period. Among PPCI patients, median door-to-balloon times decreased from 94 to 64 minutes (P<0.0001) over the same
period. In-hospital mortality was higher with ﬁbrinolysis than with PPCI (4.6% vs 3.3%, P=0.001) and did not change signiﬁcantly
over time. Patients receiving ﬁbrinolysis were less likely to receive defect-free care compared with their PPCI counterparts.
Conclusions-—Use of ﬁbrinolysis for STEMI has decreased over time with concomitant worsening of door-to-needle times. Over the
same time period, use of PPCI increased with improvement in door-to-balloon times. In-hospital mortality was higher with
ﬁbrinolysis than with PPCI. As reperfusion for STEMI continues to shift from ﬁbrinolysis to PPCI, it will be critical to ensure that
door-to-needle times and outcomes do not worsen. ( J Am Heart Assoc. 2016;5:e004113 doi: 10.1161/JAHA.116.004113)
Key Words: ﬁbrinolysis • myocardial infarction • outcome and process assessment • primary percutaneous coronary
intervention
T he 2013 American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines for
ST-elevation myocardial infarction (STEMI) recommend
emergent reperfusion of patients presenting with STEMI with
a goal ﬁrst medical contact (FMC)-to-device time of ≤90 min-
utes for patients undergoing primary percutaneous coronary
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intervention (PPCI) and presenting to a PCI-capable hospital.1
For patients presenting to a non-PCI-capable hospital, the goal
FMC to device time is ≤120 minutes. The other alternative to
PPCI is ﬁbrinolysis, when timely transfer from a non-PCI-
capable to PCI-capable hospital is not feasible, with a
recommended door-to-needle (DTN) time of ≤30 minutes.
These recommendations have evolved from 20042 with goal
door-to-balloon (DTB) time for PPCI being ≤90 minutes and
have become a focus of regional and national quality
improvement initiatives.3 However, many hospitals in the
United States still do not have the capacity to perform PPCI or
do so during regular hours only, and many of them are located
in geographical areas where timely transfer for PPCI is not
feasible, resulting in failure to meet guideline-recommended
timely reperfusion with PPCI.4 A study from the Euro Heart
Survey ACS-III database examined temporal trends in reper-
fusion in STEMI patients and found an overall decrease in
ﬁbrinolytic use with an increase in timely ﬁbrinolysis from
61.7% to 71.1% with a concomitant decrease in DTN time
from 20 to 15 minutes between 2006 and 2008.5 It is unclear
whether a parallel improvement in the timeliness of reperfu-
sion with ﬁbrinolytic therapy has been observed in the United
States and whether it has inﬂuenced in-hospital mortality.
Furthermore, compliance with acute myocardial infarction
(AMI) performance measures6 in patients receiving ﬁbrinolysis
is not known.
Therefore, we aimed to examine the frequency and
temporal pattern of ﬁbrinolytic use compared to PPCI in
patients with STEMI enrolled in the Get With the Guidelines—
Coronary Artery Disease (GWTG-CAD) database. We also
evaluated the predictors of ﬁbrinolytic use and the timeliness
of reperfusion with either strategy and compared in-hospital
mortality and performance measures in patients receiving
ﬁbrinolysis versus PPCI.
Methods
Study Population
The GWTG-CAD database was launched in 2000 and repre-
sents a national, prospective, observational registry and
quality improvement initiative established by the American
Heart Association (AHA).7-10 It is a collaborative effort among
researchers, professional organizations, and hospitals to
provide feedback on performance and strategies to improve
the care of patients with CAD. The details of the program have
been described elsewhere.10 The database includes teaching
and nonteaching, rural and urban, large and small hospitals,
and community and tertiary referral hospitals from all census
regions of the United States. Clinical information on patient
demographics, medical history, symptoms on arrival, results
of laboratory testing, in-hospital treatment and events,
discharge treatment and counseling, and on patient disposi-
tion is submitted using an online, interactive case report form
and patient management tool (Patient Management Tool,
Outcome Sciences Inc, Cambridge, MA). Hospitals are
encouraged to enroll all eligible patients consecutively with
case ﬁnding preferentially based on clinical identiﬁcation of
patients.11 All participating institutions were required to
comply with local regulatory and privacy guidelines and to
submit the GWTG-CAD protocol for review and approval by
their institutional review boards. Because data were used
primarily at each local site for quality improvement, sites were
granted a waiver of informed consent under the common rule.
Cohort Development and Deﬁnitions
Between January 1, 2003 and December 31, 2008, data were
available on 238 465 patients enrolled from 415 hospitals
participating in the GWTG-CAD program who were hospital-
ized with a conﬁrmed clinical diagnosis of CAD—including
patients with acute coronary syndromes, those with stable
CAD hospitalized for revascularization, and those with docu-
mented CAD hospitalized for reasons other than heart failure.
Hospitals with >25% missing from the medical history panel
and patients with unrecorded sex were excluded from the
analyses. Patients were excluded if they were not diagnosed
with STEMI, did not receive ﬁbrinolysis or primary PCI, had
missing discharge status, were transferred to another acute
care facility, or left against medical advice (Figure 1). Sites
with fewer than 5 patients after the prior exclusions were also
excluded. Following these exclusions, our study population
consisted of 29 190 STEMI patients from 229 sites.
Patients who had procedures listed as PCI, PCI with stent,
or percutaneous transluminal angioplasty (PTCA) and had not
received ﬁbrinolytics were classiﬁed as patients receiving
PPCI.
Study Outcomes and Measures
Modality of reperfusion (ﬁbrinolytic therapy vs PPCI) was the
primary independent variable. We studied the following
outcomes: (1) the overall frequency of ﬁbrinolysis, (2) the
frequency of timely reperfusion with ﬁbrinolysis (DTN
≤30 minutes) and PPCI (door-to-balloon (DTB) ≤90 minutes),
and (3) the association of ﬁbrinolysis with in-hospital mortality
and compliance with AMI performance measures of the
GWTG-CAD program in patients presenting with STEMI. We
also assessed the temporal trends in ﬁbrinolytic use, time-
liness of reperfusion, in-hospital mortality, and performance
measure compliance during the study period.
The performance measures of the GWTG-CAD program
have been previously described8 and included (1) aspirin
therapy within 24 hours of acute myocardial infarction (AMI),
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(2) aspirin therapy at discharge, (3) smoking cessation
counseling for eligible patients, (4) angiotensin-converting
enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
therapy in patients with left ventricular systolic dysfunction at
discharge, (5)b-blocker (BB) therapy at discharge, and (6)
lipid-lowering therapy for patients with low-density lipoprotein
(LDL) cholesterol levels >100 mg/dL. A composite perfor-
mance measure of compliance termed “defect-free care” was
also assessed and deﬁned as achievement of all 6 GWTG-CAD
performance measures.12 Length of stay was also examined.
Statistical Analyses
For the descriptive analyses, patients’ sociodemographic, insur-
ance type andmedical history variables, hospital characteristics,
clinical performance measures, and in-hospital mortality rates
were comparedbetweenﬁbrinolytic therapy andPPCI. Datawere
reported as meanSD values for continuous variables (or
medians and interquartile ranges, 25th-75th percentiles) and as
percentages for categorical variables. Categorical and continu-
ous variables were compared with the use of the Pearson v2 and
Wilcoxon rank-sum tests, respectively.
A Cochran-Armitage test was performed to assess the
temporal trend in the timeliness of reperfusion during the
study period. Multivariable logistic regression analyses were
used to examine the predictors of ﬁbrinolytic use and delayed
therapy (DTN >30 minutes or DTB >90 minutes) as well as to
evaluate the association of ﬁbrinolysis and timely reperfusion
with in-hospital outcomes. The generalized estimating equa-
tion method with exchangeable working correlation structure
was used to account for within-hospital clustering because
patients at the same hospital are more likely to have similar
treatment relative to patients in other hospitals. Sites not
capable of performing PCI were excluded from the analysis of
therapy type. Transfer-in patients and sites not capable of PCI
were also excluded from the analysis of delayed DTB time. The
regression models adjusted for the following covariates:
patient demographics (age, sex, race, height, weight, blood
pressure, insurance), medical history variables (anemia, atrial
ﬁbrillation, atrial ﬂutter, CAD, chronic obstructive pulmonary
disease [COPD] or asthma, cardiac resynchronization therapy
—deﬁbrillator [CRT-D], CRT-pacing [CRT-P], cerebrovascular
accident [CVA]/transient ischemic attack [TIA], depression,
diabetes, dialysis, heart failure, hyperlipidemia, hypertension,
ICD only, pacemaker, peripheral vascular disease [PVD],
coronary artery bypass graft [CABG], prior myocardial infarc-
tion [MI], prior PCI, renal insufﬁciency, valvular heart disease,
prior CABG, smoking), arrival time (off hours vs regular hours),
Figure 1. Study cohort development and exclusions. STEMI indicates ST elevation myocardial infarction.
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hospital characteristics (region, hospital type, number of
beds, rural vs urban, capability of cardiothoracic surgery), and
admission year. Additional analyses included comparisons of
in-hospital outcomes and performance measure compliance
between patients who received timely therapy and those who
did not (DTN ≤30 minutes vs DTN >30 minutes, and DTB
≤90 minutes vs DTB >90 minutes). Most variables had
complete data or had a missing rate <3%, with the exception
of insurance, weight, and BMI, which had 7% missing. We used
multiple imputation for missing values when performing
logistic regression.
A P<0.05 was considered statistically signiﬁcant for all
tests, and all tests of statistical signiﬁcance were 2-tailed. All
statistical analyses were performed centrally at the Duke
Clinical Research Institute (DCRI, Durham, NC) with SAS
software (version 9.1, SAS Institute, Cary, NC).
Results
Study exclusions are shown in Figure 1. We evaluated a total
of 238 465 patients from 415 hospitals between January 1,
2003 and December 31, 2008 from the GWTG-CAD database.
After excluding patients not diagnosed with STEMI, those not
undergoing reperfusion therapy, patients with missing dis-
charge data, transfer-out patients, and those leaving against
medical advice, the ﬁnal study cohort included 29 190 STEMI
patients from 229 hospitals. Of those, 2441 (8.4%) patients
received ﬁbrinolysis in 180 hospitals. Overall, 38.2%
of patients achieved timely ﬁbrinolysis with a median DTN
of 37 minutes (IQR 21-65). During hospitalization, 74.4% of
these patients underwent coronary angiography, 58.8%
underwent PCI, and 7.2% underwent CABG surgery.
Baseline characteristics of patients receiving ﬁbrinolysis
compared to PPCI are summarized in Table 1. Patients
receiving ﬁbrinolysis had a lower prevalence of prior CAD
and dyslipidemia, higher prevalence of diabetes and hyper-
tension, and presented to rural hospitals more frequently.
Patients receiving PPCI were less likely to receive CABG
during their hospitalization. Overall, 54.8% of patients under-
going PPCI received timely PPCI (DTB ≤90 minutes) with a
median DTB of 80 (IQR 51-120) minutes.
During the study period, ﬁbrinolysis decreased from 20.5%
in 2003 to 3.7% in 2008 (P<0.0001) (Figure 2A). There was an
increase in median DTN (36 to 60 minutes; P=0.005), and
median DTB decreased (94 to 64 minutes; P<0.0001). As a
result, there was a decrease in the proportion of patients with
timely ﬁbrinolysis and an increase in the proportion of
patients with timely PPCI (Figure 2B). In-hospital mortality
with ﬁbrinolysis was higher than that with PPCI (4.6% vs 3.3%,
P=0.001) and was consistent during the study period
(Figure 2C). Median length of stay was longer for patients
receiving ﬁbrinolysis compared to PPCI (4 [IQR 3-6] vs 3 [IQR
2-5] days, P<0.0001) (Table 2).
Independent predictors of ﬁbrinolytic use included off-hour
presentation, Midwest and southern regions versus northeast,
rural location, smoking, and no hyperlipidemia. Independent
predictors of delayed ﬁbrinolysis and delayed PPCI are
summarized in Tables S1 through S3.
Performance measures and defect-free care were lower
among patients receiving ﬁbrinolysis compared to PPCI
(defect-free care 81.1% vs 90.1%, P<0.0001) (Table 3).
However, in patients receiving ﬁbrinolysis, defect-free care
increased over the study period (74% to 91%, P<0.0001). No
difference in compliance with performance measures was
noted between patients with timely versus delayed ﬁbrinol-
ysis, although patients with timely PPCI were more likely to
receive defect-free care than patients with delayed PPCI
(93.3% vs 87.7%, P<0.0001).
After multivariable adjustment, there was no signiﬁcant
association of reperfusion therapy type or timely ﬁbrinolysis
(DTN ≤30 minutes) with in-hospital mortality. However, an
association between timely PPCI (DTB ≤90 minutes) and in-
hospital mortality was seen (OR 0.63, 95% CI 0.49-0.79;
P=0.0001) (Table 4).
Discussion
Our data provide an insight into the use of ﬁbrinolytic therapy for
acute reperfusion treatment of STEMI in a large national registry
of hospitals in the United States. We have shown that 8.4% of
patients presenting with STEMI received ﬁbrinolysis, of whom
only 38.2% achieved timely DTN ≤30 minutes. The use of
ﬁbrinolytic therapy decreased from 20.5% in 2003 to 3.7% in
2008, and its timeliness worsened, with nearly doubling in
median DTN times from 36 to 60 minutes (P=0.005). DTB
signiﬁcantly improved during the same time period. Performance
measures and defect-free care improved in patients receiving
ﬁbrinolysis over the study period. Therefore, it is important to
continue to monitor timeliness and outcomes of ﬁbrinolysis in
eligible patients as use of ﬁbrinolysis becomes more infrequent.
PPCI is associated with improved mortality compared to
ﬁbrinolytic therapy in patients presenting with STEMI and is
the preferred reperfusion strategy when feasible in a timely
manner.1,13 It has been shown that for every 10-minute delay
in performing PCI, the mortality beneﬁt of PCI compared to
ﬁbrinolysis is decreased by 1%, and both reperfusion strate-
gies become almost equivalent at 62 minutes.14 However,
only one third of acute care hospitals in the United States
have around-the-clock PCI capability.15,16 Further, despite
investment of effort and resources, limited reductions in
interhospital transfer times have occurred.17 The guidelines
for management of patients with STEMI have evolved with the
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1996 and 1999 recommendations18 stating that PPCI was an
alternative to ﬁbrinolytic therapy for reperfusion and 2004
recommendations2 stating that PPCI was the preferred
reperfusion strategy with ﬁbrinolysis being used when timely
PPCI could not be delivered. This likely inﬂuenced practice
patterns and is consistent with the temporal trend we found in
our study with increasing use of PPCI and declining ﬁbrinolytic
use. The current guidelines for STEMI recommend ﬁbrinolysis
for eligible patients presenting to non-PCI-capable hospitals
who would not receive FMC-to-device time ≤120 minutes on
Table 1. Baseline Characteristics of Patients With STEMI Receiving Fibrinolysis vs PPCI
Variable, n (%) Unless Otherwise Indicated
Fibrinolysis
n=2441 (%)*
PPCI
n=26 749 (%)* P Value
Demographics
Age (meanstandard deviation), y 60.413.2 60.813.2 0.19
Male 1729 (70.8) 18 991 (71.0) 0.86
Race
White 1748 (73.2) 20 875 (79.4) <0.001
Black 192 (8.0) 1643 (6.3)
Hispanic 290 (12.1) 1814 (6.9)
BMI, meanSD 28.76.3 28.96.0 0.19
Insurance type†
Medicare 481 (22.1) 5611 (22.6) <0.001
Other 1118 (51.4) 13 969 (56.3)
None 415 (19.1) 3908 (15.8)
Medical history
CAD 158 (7.2) 2636 (10.4) <0.001
Atrial fibrillation 73 (3.3) 803 (3.2) 0.71
Diabetes 598 (27.2) 5762 (22.8) <0.001
Hypertension 1331 (60.6) 14 704 (58.2) 0.03
Dyslipidemia 851 (38.8) 11 884 (47.0) <0.001
Heart failure 138 (6.3) 1252 (5.0) 0.01
Prior PCI 19 (0.9) 539 (2.1) <0.001
Prior CABG 10 (0.5) 158 (0.6) 0.33
COPD or asthma 223 (10.2) 2203 (8.7) 0.02
Renal insufficiency 88 (4.0) 793 (3.1) 0.03
CVA/TIA 90 (4.1) 1069 (4.2) 0.77
Smoking 999 (46.9) 10 748 (43.3) 0.001
Hospital characteristics
Region
West 525 (21.5) 6021 (22.5) <0.001
South 1068 (43.8) 7947 (29.7)
Midwest 504 (20.7) 7466 (27.9)
Northeast 344 (14.1) 5315 (19.9)
Teaching hospital 1246 (51.1) 17 324 (64.8) <0.0001
Number of beds (meanSD) 441.8279.7 456.3274.7 <0.0001
Rural location 223 (9.1) 1153 (4.7) <0.001
BMI indicates body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; PCI,
percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention; SD, standard deviation; STEMI, ST elevation myocardial infarction; TIA, transient ischemic attack.
*Percentage for each characteristic calculated out of available data.
†Patients can have more than 1 type of insurance.
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transfer. Therefore, ﬁbrinolysis plays a key role in the
management of eligible STEMI patients unable to receive
timely PPCI.
A recent report from the National Cardiovascular Data
Registry (NCDR)4 showed that, among patients presenting to
a non-PCI-capable hospital and transferred for PPCI, only
51.3% of patients achieved DTB ≤120 minutes. Among
patients eligible to receive ﬁbrinolysis with estimated drive
time over 60 minutes, only 52.7% received ﬁbrinolysis.
Median DTN was 34 minutes, and only 43.8% achieved DTN
≤30 minutes, which is consistent with our results. The in-
hospital mortality of patients receiving ﬁbrinolysis was 3.7% in
A
B
Figure 2. A, Annual trends in ﬁbrinolysis and PPCI for patients with STEMI in the GWTG-
CAD database. The frequency of ﬁbrinolysis decreased from 20.5% in 2003 to 3.7% in 2008
while PPCI increased from 79.5% in 2003 to 96.3% in 2008 (P value from Cochran-Armitage
test <0.0001). B, Annual trends in the proportion of patients receiving timely reperfusion
with ﬁbrinolysis (DTN ≤30 minutes) and PPCI (DTB ≤90 minutes) for patients with STEMI in
the GWTG-CAD database. The frequency of timely ﬁbrinolysis peaked at 45.8% in 2006 and
decreased to 22.9% in 2008 while timely PPCI increased from 37.0% in 2003 to 76.3% in
2008. (P value from Cochran-Armitage test=0.2769 for DTN ≤30 minutes; P<0.0001 for
DTB ≤90 minutes.) C, Annual trends of in-hospital mortality for patients receiving
ﬁbrinolysis and PPCI. In-hospital mortality was 4.6% in patients receiving ﬁbrinolysis and
3.3% in patients receiving PPCI and did not change signiﬁcantly over time. (P value from
Cochran-Armitage test=0.9473 for ﬁbrinolytics patients, P=0.1474 for PPCI patients.) CAD
indicates coronary artery disease; DTB, door to balloon; DTN, door to needle; GWTG, Get
With the Guidelines; PPCI, primary percutaneous coronary intervention; STEMI, ST elevation
myocardial infarction.
DOI: 10.1161/JAHA.116.004113 Journal of the American Heart Association 6
Temporal Patterns of Fibrinolytic Use in STEMI Hira et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
that report,4 which is also similar to our ﬁndings. In-hospital
mortality of patients undergoing PPCI in that report was 3.9%,
which is higher than the 3.3% seen in our study and may have
been due to delay in transfer with median DTB time of
126 minutes. Possible reasons for the worsening in the
timeliness of ﬁbrinolysis include the overall decrease in the
frequency of ﬁbrinolytic use, resulting in unfamiliarity with its
administration protocols, complex care coordination between
transferring and receiving centers resulting in delays and
cancellation of some transfers, and the perceived hazards of
ﬁbrinolytic therapy (eg, intracranial hemorrhage) despite
delayed transfer resulting in reluctance in its use.
Another report from the NCDR examined temporal trends
in DTB time.19 They found that between 2005 and 2009,
median DTB time had decreased from 83 to 67 minutes while
the percentage of patients achieving timely PPCI (DTB
≤90 minutes) had increased from 59.7% to 83.1%. Despite
these signiﬁcant improvements in DTB times, they noted no
signiﬁcant change in in-hospital mortality at 4.7%. Our results
corroborate these ﬁndings. We previously argued that some of
the time differential in DTB times observed in clinical studies
may be too small to exert a meaningful clinical impact,
especially when short-term outcomes are examined.20,21 A
Table 2. In-Hospital Outcomes Between Patients With STEMI
Receiving Fibrinolysis vs PPCI
Variable
Fibrinolytics
n=2441 (%)
PPCI
n=26 749 (%) P Value
In-hospital mortality 112 (4.6) 890 (3.3) 0.001
Length of stay
(median, IQR), days
4.0 (3-6) 3.0 (2-5) <0.0001
Length of stay >4 days 663 (38.9) 5268 (27.8) <0.0001
Door-to-reperfusion time
DTN, median (IQR),
minutes
37 (21–65) n/a
DTN ≤30 minutes (%) 731 (38.2) n/a
DTB, median (IQR),
minutes
n/a 80 (51-120)
DTB ≤90 minutes (%) n/a 10 907 (54.8)
DTB indicates door to balloon; DTN, door to needle; IQR, interquartile range; PPCI,
primary percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.
Table 3. Adherence to CAD Performance Measures Between
Patients With STEMI Receiving Fibrinolysis vs PPCI
Performance Measure
Fibrinolytics
N=2441 (%)
Primary PCI
n=26 749 (%) P Value
ACE-I or ARB for LVSD 342 (83.2) 4440 (90.2) <0.0001
Aspirin at discharge 2175 (97.0) 24 685 (98.6) <0.0001
Aspirin within 24 hours 1510 (93.5) 17 707 (96.7) <0.0001
Β-Βlockers at discharge 2061 (95.0) 23 616 (97.9) <0.0001
Patients with
LDL-C >100 mg/dL
who received statins
or lipid-lowering drugs
783 (90.2) 9090 (95.3) <0.0001
Smoking cessation for CAD 980 (88.9) 10 773 (94.7) <0.0001
Defect-free care
(100% compliance
with performance
measures)
1932 (81.1) 23 631 (90.1) <0.0001
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; CAD, coronary artery disease; LDL, low-density lipoprotein; LVSD, left
ventricular systolic dysfunction; PPCI, primary percutaneous coronary intervention;
STEMI, ST elevation myocardial infarction.
C
Figure 2. Continued
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prior report from the National Registry of Myocardial Infarc-
tion (NRMI)22 evaluating reperfusion strategies in STEMI
patients in 1990 through 2006 found a decrease in ﬁbrinol-
ysis from 52.5% to 27.6% with a nearly linear decline in DTN
from 59 to 29 minutes and a corresponding decrease in
mortality from 7.0% to 6.0% over the study period. The relative
improvement in mortality attributable to improvements in DTN
time was 16.3%. The median DTN in our study was lowest in
2006 (31 minutes), similar to the results from this study. This
was followed by an increase to 43.5 minutes in 2007 and
60 minutes in 2008. Overall, the mortality rates in our study
were among the lowest reported with both reperfusion
strategies. The lack of signiﬁcant change in in-hospital
mortality is consistent with other reports and can be
attributed to already marked improvement in in-hospital
mortality rates, making it difﬁcult to achieve further incre-
mental beneﬁt. One may also argue that the total ischemic
time from onset of arterial occlusion to reperfusion, rather
than medical contact to reperfusion times, may play a more
important role in short-term in-hospital outcomes. This may
also be related to a low event rate among a small number of
patients who received ﬁbrinolysis in our study.
Further, there has been some renewed interest in ﬁbrinol-
ysis and pharmacoinvasive strategies in which cardiac
catheterization is routinely performed within 6 hours of
ﬁbrinolytic administration. The Trial of Routine Angioplasty
and Stenting After Fibrinolysis to Enhance Reperfusion in
Acute Myocardial Infarction (TRANSFER-AMI)23 showed that
high-risk STEMI patients receiving ﬁbrinolysis and routine
early PCI had improved short-term outcomes compared to
patients receiving standard therapy and delayed PCI. A report
of 73 Belgian hospitals24 found that modern ﬁbrinolytic
strategies substantially attenuated the mortality beneﬁt of
PPCI over ﬁbrinolysis except for patients in the highest-risk
subgroup with thrombolysis in myocardial infarction (TIMI)
scores of 7 to 14. The Strategic Reperfusion Early After
Myocardial Infarction (STREAM)25 study showed that in
patients with STEMI unable to undergo PPCI within 1 hour,
prehospital ﬁbrinolysis and angiography within 6 to 24 hours
resulted in effective reperfusion compared to PPCI alone.
However, ﬁbrinolysis was associated with a slight increase in
intracranial bleeding.26 Therefore, given the delays in transfer
times from non-PCI-capable hospitals and the possible lack of
mortality beneﬁt of PPCI over ﬁbrinolysis in low-risk patients,
the role of timely reperfusion with ﬁbrinolysis followed by
routine angiography needs to reconsidered.
The ACC/AHA emphasis on care of patients with STEMI
has resulted in the public reporting of these performance
measures,3 which are also now tied to reimbursement from
the Centers for Medicare and Medicaid Services27 and
therefore have ﬁnancial implications for institutions. Our
results, as well as those of others, depict the signiﬁcant
improvements seen in DTB times and timely PPCI. However,
as our study has shown, this improvement has not occurred in
DTN times and timely ﬁbrinolysis. Additionally, the improve-
ment noted in defect-free care and adherence to performance
measures in patients receiving either reperfusion strategy
over the study period indicates the important role played by
quality improvement programs. However, defect-free care was
found to be signiﬁcantly lower in patients receiving ﬁbrinolysis
and should raise concerns in patients receiving ﬁbrinolysis as
use continues to decrease.
Study Limitations
Our study has several limitations. First, the GWTG program is
a quality improvement program, and participation is voluntary.
Therefore, these hospitals may be highly motivated for quality
improvement, and results may not be fully representative of
national care patterns and clinical outcomes. Second, data on
prehospital delay or treatments, 24-hour PCI capability of
hospitals, bleeding outcomes, or postdischarge mortality and
morbidity were not available. Third, eligibility, type, and time
of treatment received were based on documentation in the
medical record and were thus dependent on the accuracy of
this documentation. Fourth, there might be other measured or
unmeasured confounding variables that, had they been
adjusted for, would have altered outcomes. Finally, trends in
reperfusion strategies were assessed between 2003 and
2008, and therefore, contemporary patterns of ﬁbrinolysis
may be different. However, our study demonstrates the
importance of tracking and improving DTN times in hospitals
that do not perform PPCI around the clock as well as the need
for contemporary data in trends and outcomes of ﬁbrinolytic
use for STEMI.
Conclusions
The use of ﬁbrinolytic therapy for STEMI has decreased from
2003 to 2008, in contradistinction to the use of PPCI. Despite
improvements in timely PPCI and defect-free care, a signif-
icant delay in timely ﬁbrinolysis was noted over time. In-
hospital mortality among STEMI patients receiving ﬁbrinolysis
remained unchanged over the study period and worse than
that of their PPCI counterparts. Our ﬁndings highlight
important opportunities to improve the use of ﬁbrinolytic
therapy and its timeliness among eligible STEMI patients.
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SUPPLEMENTAL MATERIAL 
Table S1. Predictors of fibrinolytic use vs PPCI. 
Variable Level OR (95% CI) P-value 
Admission year (ref. 2003) 2004 0.61 (0.51-0.73) 
<0.0001 
 2005 0.36 (0.28-0.47) 
 2006 0.29 (0.21-0.38) 
 2007 0.16 (0.11-0.23) 
 2008 0.16 (0.10-0.25) 
Age (per 5 years)  0.99 (0.96-1.02) 0.41 
Sex (ref. Male) Female 1.05 (0.95-1.16) 0.36 
Race (ref. Caucasian) non-Caucasian 1.03 (0.92-1.17) 0.59 
Hour of arrival 
(ref. off hours weekends and nights) 
Regular hours 
(weekdays 7am - 7pm) 
0.70 (0.63-0.77) 
<0.0001 
Insurance (ref. other) Medicaid 0.97 (0.79-1.20) 
0.67 
 Medicare 1.08 (0.92-1.26) 
 No Insurance/Not 
Documented/UT 
1.06 (0.92-1.22) 
Past Medical/Surgical history 
CABG Yes 1.47 (0.95-2.28) 0.08 
CAD Yes 1.17 (0.93-1.46) 0.17 
Diabetes Yes 1.08 (0.97-1.20) 0.18 
Heart failure Yes 1.05 (0.80-1.38) 0.73 
Hyperlipidemia Yes 0.88 (0.80-0.97) 0.009 
Hypertension Yes 1.01 (0.92-1.10) 0.84 
MI Yes 1.02 (0.90-1.16) 0.75 
PCI Yes 1.07 (0.63-1.81) 0.78 
Smoking Yes 1.10 (1.00-1.20) 0.04 
Number of beds (per 50 beds)  1.03 (0.99-1.08) 0.17 
 PPCI – Primary percutaneous coronary intervention, OR – odds ratio, CI – Confidence interval, 
CABG - Coronary artery bypass graft, CAD – Coronary artery disease, MI - myocardial 
infarction, PCI - percutaneous coronary intervention, CT – Cardiothoracic.  
  
CABG/CT capable hospital Yes 1.90 (0.81-4.45) 0.14 
Rural location Yes 2.51 (1.04-6.07) 0.04 
Table S2. Predictors of delayed fibrinolysis (DTN > 30 minutes) vs timely fibrinolysis (DTN < 
30 minutes). 
Variable Level OR (95% CI) P-value 
Admission year (ref. 2003) 2004 0.95 (0.70-1.30) 
0.02 
 2005 1.15 (0.75-1.76) 
 2006 0.78 (0.49-1.25) 
 2007 1.38 (0.84-2.28) 
 2008 2.31 (1.08-4.93) 
Age (per 5 years)  1.01 (0.96-1.07) 0.67 
Sex (ref. Male) Female 1.05 (0.83-1.33) 0.67 
Race (ref. Caucasian) non-Caucasian 0.92 (0.70-1.21) 0.56 
Hour of arrival (ref. off hours 
(weekends and nights 7pm-7am)) 
Regular hours (weekdays 7am 
- 7pm) 
0.97 (0.78-1.21) 
0.81 
Insurance (ref. other) Medicaid 0.80 (0.54-1.20) 
0.15 
 Medicare 1.27 (0.91-1.77) 
 No Insurance/Not 
Documented/UT 
1.05 (0.77-1.42) 
Past Medical/Surgical history 
CAD Yes 1.14 (0.77-1.71) 0.51 
COPD Yes 1.29 (0.93-1.80) 0.12 
Diabetes Yes 1.27 (1.02-1.57) 0.03 
Heart failure Yes 1.48 (1.03-2.13) 0.04 
Hyperlipidemia Yes 1.04 (0.83-1.31) 0.73 
Hypertension Yes 1.10 (0.88-1.37) 0.41 
MI Yes 0.94 (0.72-1.23) 0.66 
PCI Yes 0.57 (0.23-1.41) 0.22 
Smoking Yes 0.91 (0.73-1.12) 0.36 
  
PPCI – Primary percutaneous coronary intervention, DTN- Door to needle, DTB – Door to 
balloon, OR – odds ratio, CI – Confidence interval, CAD – Coronary artery disease, COPD – 
chronic obstructive pulmonary disease, MI - myocardial infarction, PCI - percutaneous coronary 
intervention, CABG - Coronary artery bypass graft, CT – Cardiothoracic. 
 
 
  
  
Number of beds < 600 (per 50 beds)  0.98 (0.92-1.04) 0.46 
Number of beds > 600 (per 50 beds)  1.07 (1.00-1.14) 0.04 
CABG/CT capable hospital Yes 1.03 (0.60-1.76) 0.91 
Rural location Yes 1.19 (0.57-2.49) 0.65 
Table S3. Predictors of delayed PPCI (DTB > 90 minutes) vs timely PPCI (DTB < 90 minutes). 
Variable Level OR (95% CI) P value 
Admission year (ref. 2003) 2004 1.03 (0.79-1.34) 
<0.0001 
 2005 0.84 (0.62-1.14) 
 2006 0.58 (0.43-0.79) 
 2007 0.33 (0.23-0.46) 
 2008 0.21 (0.15-0.29) 
Age < 53 (per 5 years)  0.94 (0.89-0.99) 0.01 
Age > 53 (per 5 years)  1.08 (1.05-1.10) <0.0001 
Sex (ref. Male) Female 1.08 (0.98-1.20) 0.11 
Hour of arrival (ref. off hours 
(weekends and nights 7pm-7am)) 
Regular hours (weekdays 
7am - 7pm) 
0.45 (0.40-0.51) 
<.0001 
Insurance (ref. other) Medicaid 1.08 (0.88-1.31) 
0.65 
 Medicare 0.96 (0.88-1.05) 
 No Insurance/Not 
Documented/UT 
1.02 (0.91-1.15) 
PaPPast Medical/Surgical history 
CAD Yes 1.01 (0.86-1.19) 0.90 
Diabetes Yes 1.18 (1.08-1.28) 0.0002 
Dialysis Yes 1.35 (0.69-2.63) 0.33 
Heart failure Yes 1.19 (1.00-1.43) 0.06 
Hyperlipidemia Yes 1.04 (0.96-1.12) 0.37 
Hypertension Yes 1.11 (1.02-1.20) 0.01 
MI Yes 1.15 (1.03-1.30) 0.02 
Renal insufficiency Yes 1.33 (1.06-1.68) 0.01 
Smoking Yes 0.86 (0.78-0.94) 0.001 
Valvular heart disease Yes 0.77 (0.24-2.50) 0.62 
Number of beds < 400 (per 50 
beds) 
 1.09 (1.00-1.19) 0.05 
  
PPCI – Primary percutaneous coronary intervention, DTB – Door to balloon, OR – odds ratio, CI 
– Confidence interval, CAD – Coronary artery disease, MI - myocardial infarction, CABG - 
Coronary artery bypass graft, CT – Cardiothoracic. 
 
 
Number of beds > 400 (per 50 
beds) 
 1.01 (0.98-1.04) 0.60 
Race (ref. Caucasian) non-Caucasian 1.10 (0.98-1.23) 0.10 
CABG/CT capable hospital Yes 0.60 (0.38-0.95) 0.03 
Rural location Yes 1.77 (1.09-2.87) 0.02 
